{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"10.6","value":"0"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants who achieved a confirmed CR or PR based on investigator assessment from start of treatment until PD or start of subsequent anti-cancer therapy or cancer-related surgery, whichever was earlier, as per RANO criteria for primary brain tumors or RECIST v 1.1 criteria for all other solid tumors. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the treatment started. In addition, the sum must have an absolute increase from nadir of 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG000","title":"Synovial Sarcoma: Cohort 2"},{"description":"Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG001","title":"ES 1600 mg: Cohort 8"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who received at least 1 dose of tazemetostat.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed at screening and every 8 weeks beginning at Cycle 3 Day 1, until disease progression or the start of subsequent anti-cancer therapy, whichever occurred first, up to 5.75 years (cycle duration: 28 days)","title":"Cohorts 2 and 8: Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}